PSS33 - SECUKINUMAB AS FIRST BIOLOGIC TREATMENT: A COST PER RESPONDER ANALYSIS COMPARED WITH LICENSED BIOLOGICS, FOR MODERATE TO SEVERE PSORIASIS IN ARGENTINA